Clinical Updates Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial MedXY Editorial Team Sep 16, 2025
Highlight
Metformin combined with chemoradiotherapy is safe and well-tolerated in locally advanced cervical cancer patients.
The addition of metformin does not increase severe adverse events compared to chemoradiotherapy alone.
MRI and tumor biopsy assessments for hypoxia biomarkers were successfully implemented throughout the study, affirming feasibility.
Initial safety evaluations show no concerning early increase in tumor hypoxia with metformin administration.
Study Background and Disease Burden MedXY registered readers
Sign in free to continue reading Create or use your MedXY account to unlock the complete article.
Sign in / Register This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Like 0 Dislike 0 Favorite 0 Share 0